Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escitalopram + sertraline is a combination of two selective serotonin reuptake inhibitors (SSRIs), each used individually to treat major depressive disorder and anxiety disorders. Both drugs act primarily by inhibiting the serotonin transporter (SERT), increasing synaptic serotonin levels in the brain. Escitalopram is notable for its high selectivity for SERT and additional allosteric inhibition, which may contribute to its efficacy and tolerability. Sertraline also selectively inhibits SERT but has a slightly broader pharmacological profile compared to escitalopram. The combination of these two SSRIs is not standard clinical practice due to an increased risk of serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic activity[1][4][8]. Both drugs are developed for the treatment of depression, generalized anxiety disorder, panic disorder, social anxiety disorder, and related conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + sertraline.